Allogene Therapeutics Announces Oral Presentation of Phase
Initial Data Provide Proof-of-Concept for an anti-CD70 AlloCAR T Candidate in Patients with Renal Cell Carcinoma (RCC) Who Received Prior Immune Checkpoint...
Source: globenewswire.com